Drug and pro-drug substrates and pseudo-substrates of human butyrylcholinesterase.

Arylacylamide Butyrylcholinesterase Carbamate Carboxylesterase Ester Organophosphate Pro-drug

Journal

Biochemical pharmacology
ISSN: 1873-2968
Titre abrégé: Biochem Pharmacol
Pays: England
ID NLM: 0101032

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 20 09 2023
revised: 03 11 2023
accepted: 03 11 2023
medline: 4 12 2023
pubmed: 17 11 2023
entrez: 16 11 2023
Statut: ppublish

Résumé

Butyrylcholinesterase (BChE) is present in plasma and numerous cells and organs. Its physiological function(s) is(are) still unclear. However, this enzyme is of pharmacological and toxicological importance. It displays a broad specificity and is capable of hydrolyzing a wide range of substrates with turnovers differing by several orders of magnitude. Nowaday, these substrates include more than two dozen carboxyl-ester drugs, numerous acetylated prodrugs, and transition state analogues of acetylcholine. In addition, BChE displays a promiscuous hydrolytic activity toward amide bonds of arylacylamides, and slowly hydrolyzes carbamyl- and phosphoryl-esters. Certain pseudo-substrates like carbamates and organophosphates are major drugs of potential medical interest. The existence of a large genetic poly-allelism, affecting the catalytic properties of BChE is at the origin of clinical complications in the use of certain drugs catabolized by BChE. The number of drugs and prodrugs hydrolyzed by BChE is expected to increase in the future. However, very few quantitative data (K

Identifiants

pubmed: 37972875
pii: S0006-2952(23)00503-8
doi: 10.1016/j.bcp.2023.115910
pii:
doi:

Substances chimiques

Butyrylcholinesterase EC 3.1.1.8
Prodrugs 0
Succinylcholine J2R869A8YF

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115910

Informations de copyright

Copyright © 2023. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Patrick Masson (P)

Laboratory of Biochemical Neuropharmacology, Kazan Federal University, Kazan, Russian Federation. Electronic address: pym.masson@free.fr.

Zukhra Shaihutdinova (Z)

Laboratory of Biochemical Neuropharmacology, Kazan Federal University, Kazan, Russian Federation.

Oksana Lockridge (O)

Eppley Institute, University of Nebraska Medical Center, Omaha NE, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH